Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
#4PRI RANKED
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
semaglutide · obesity-related heart failure · Heart failure with preserved ejection fraction · Heart failure with preserved ejection fraction · STEP-HFpEF trial · STEP-HFpEF DM trial · Patient-level pooled analysis · GLP-1 receptor agonist · Double-blind randomized controlled trial · Obesity · diabetes mellitus · weight loss · cardiovascular outcomes · Kansas City Cardiomyopathy Questionnaire · 6-minute walk distance · exercise capacity · NT-proBNP · C-reactive protein
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459